ArticleOpen veterinary journal2025
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Systems Biology and Structure-Based In Silico Evaluations of Quercetin-Psychobiotic Interactions for the Management of Depression.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Decoding antidengue serotype-3 (DENV-3) mechanism of natural glycosides fromOpen veterinary journal · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The potential anticancer properties of vitamin D3 (cholecalciferol) have garnered growing interest. Epidemiological and preclinical studies suggest an inverse correlation between vitamin D3 levels and CRC incidence. However, the precise molecular mechanisms and direct targets through which vitamin D3 exerts anticancer effects remain inadequately characterized. Aim: This study aimed to investigate the dual-targeting potential of vitamin D3 against two key oncogenic proteins involved in the pathogenesis of CRC: cyclin-dependent kinase 2 (CDK2), a critical regulator of cell cycle progression, and B-cell lymphoma 2 (Bcl-2), an anti-apoptotic protein implicated in tumor survival. Method: Molecular docking was performed to assess the binding affinity of vitamin D3 to CDK2 and Bcl-2. Molecular dynamics simulations were used to evaluate the stability of the docked complexes over time. Absorption, distribution, metabolism, excretion, and toxicity (ADMET) analysis was performed to predict the pharmacokinetics and safety profile of vitamin D3. Results: Docking analysis revealed strong binding affinities of vitamin D3 to both CDK2 (-9.5 kcal/mol) and Bcl-2 (-8.2 kcal/mol), suggesting stable interactions at the ATP-binding site of CDK2 and the BH3-binding groove of Bcl-2. Molecular dynamics simulations confirmed the conformational stability and sustained interactions of vitamin D3 with both targets throughout the simulation period. ADMET predictions indicated favorable oral bioavailability, low toxicity, and acceptable absorption and distribution characteristics, although solubility and plasma protein binding were limited. Conclusion: This study provides the first computational evidence that vitamin D3 may exert anticancer effects in CRC via dual mechanisms-cell cycle arrest through CDK2 inhibition and apoptosis induction through Bcl-2 modulation. These findings offer a novel perspective on the therapeutic repositioning of vitamin D3 as a multi-target agent in CRC management and warrant further validation through in vitro and in vivo studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.